SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Journal of the American College of Cardiology

Volumn 71, Issue 22, 2018, Pages 2497-2506

  Cavender, Matthew A ^a,b,o   Norhammar, Anna ^c,o   Birkeland, Kåre I ^d,e,o   Jørgensen, Marit Eika ^f,g,o   Wilding, John P ^h,o   Khunti, Kamlesh ^i,o   Fu, Alex Z ^j,o   Bodegård, Johan ^k,o   Blak, Betina T ^k,o   Wittbrodt, Eric T ^o   Thuresson, Marcus ^l,o   Fenici, Peter ^k,o   Hammar, Niklas ^c,m,o   Kosiborod, Mikhail ^n,o   Holl, Reinhard W ^o   Chen, Hungta ^o   Scheerer, Markus F ^o   Surmont, Filip ^o   Nahrebne, Kyle ^o   Gulseth, Hanne Løvdal ^o   Carstensen, Bendix ^o   Bollow, Esther ^o   García Rodríguez, Luis Alberto ^o   Cea Soriano, Lucia ^o   Cantero, Oscar Fernándex ^o   Thiel, Ellen ^o   Murphy, Brian ^o   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Baim Institute of Clinical Research   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^k ASTRAZENECA   (United Kingdom)

^l STATISTICON AB   (Sweden)

^m ASTRAZENECA R AND D   (Sweden)

ⁿ UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^o NONE

more..

Author keywords

cardiovascular disease; CVD REAL; heart failure; sodium glucose co transporter 2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; DRUG USE; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; INTERNATIONAL COOPERATION; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85047116457     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.01.085     Document Type: Article

References (28)

1. Di Angelantonio, E., Kaptoge, S., Wormser, D., et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314 (2015), 52–60.
2. Cavender, M.A., Steg, P.G., Smith, S.C. Jr., et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation 132 (2015), 923–931.
3. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
4. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
5. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
6. Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709–17.
7. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
8. da Graca, B., Filardo, G., Nicewander, D., Consequences for healthcare quality and research of the exclusion of records from the Death Master File. Circ Cardiovasc Qual Outcomes 6 (2013), 124–128.
9. Herrett, E., Gallagher, A.M., Bhaskaran, K., et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 44 (2015), 827–836.
10. Carbonari, D.M., Saine, M.E., Newcomb, C.W., et al. Use of demographic and pharmacy data to identify patients included within both the clinical practice research datalink (CPRD) and the health improvement network (THIN). Pharmacoepidemiol Drug Saf 24 (2015), 999–1003.
11. Stuart, E.A., Matching methods for causal inference: a review and a look forward. Stat Sci 25 (2010), 1–21.
12. Normand, S.T., Landrum, M.B., Guadagnoli, E., et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54 (2001), 387–398.
13. Blackstone, E.H., Comparing apples and oranges. J Thorac Cardiovasc Surg 123 (2002), 8–15.
14. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
15. Bhatt, D.L., Cavender, M.A., Are all clinical trial sites created equal?. J Am Coll Cardiol 61 (2013), 580–581.
16. Cavender, M.A., White, W.B., Jarolim, P., et al. Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation 135 (2017), 1911–1921.
17. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 989–998.
18. Laupacis, A., Sackett, D.L., Roberts, R.S., An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988), 1728–1733.
19. Devineni, D., Curtin, C.R., Polidori, D., et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53 (2013), 601–610.
20. Scheen, A.J., Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53 (2014), 213–225.
21. Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S.C., Boulton, D.W., Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53 (2014), 17–27.
22. Bakris, G.L., Fonseca, V.A., Sharma, K., Wright, E.M., Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75 (2009), 1272–1277.
23. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
24. Cavender, M.A., Kosiborod, M., Canagliflozin: cui bono?. Circulation 137 (2018), 335–337.
25. Multicenter trial to evaluate the effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI 58). NCT01730534. Available at: https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed January 19, 2018.
26. Raz, I.B.M., Mosenzon, O., Kato, E.T., et al. DECLARE-TIMI 58: design and baseline characteristics. [abstract 1245-P] Diabetes, 66, 2017, A333.
27. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
28. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease (the VERTIS CV study) (MK-8835-004). NCT01986881. Available at: https://clinicaltrials.gov/ct2/show/NCT01986881. Accessed January 19, 2018.